IV infusion Initial dose should be delivered over 90 min. If well tolerated 2nd infusion may be administered over 60 min. Subsequent infusions may be administered over 30 min if 60-min infusion is well tolerated.
Metastatic colon & rectal cancer (rectum or anus) 1st-line treatment: 5 mg/kg once every 2 wk or 7.5 mg/kg once every 3 wk. 2nd-line treatment: 5 mg/kg or 10 mg/kg once every 2 wk or 7.5 mg/kg or 15 mg/kg once every 3 wk. Continue treatment until progression of underlying disease.
Patients previously treated w/ Bevacizumab Continue w/ treatment following 1st progression.
Locally recurrent or metastatic Breast Cancer (mBC) 10 mg/kg once every 2 wk, or 15 mg/kg once every 3 wk. Continue treatment until progression of underlying disease.
Advanced, metastatic, or recurrent NSCLC 1st-line treatment in combination w/ cisplatin-based chemotherapy: 7.5 mg/kg once every 3 wk; w/ carboplatin-based chemotherapy: 15 mg/kg once every 3 wk. 1st-line treatment of NSCLC w/ EGFR activating mutations in combination w/ erlotinib: 15 mg/kg once every 3 wk, continued until disease progression.
Advanced &/or metastatic Renal Cell Cancer (mRCC) 10 mg/kg once every 2 wk, continued until progression of underlying disease.
Glioblastoma [malignant glioma (WHO grade IV)] Newly diagnosed: 10 mg/kg once every 2 wk in combination w/ temozolomide & RT for 6 wk. Following 4-wk treatment break, re-initiate (10 mg/kg once every 2 wk) in combination w/ temozolomide for up to 6 cycles of 4-wk duration. Continue treatment (15 mg/kg once every 3 wk) as single agent until disease progression after administration of up to 6 cycles of combined bevacizumab & temozolomide. Treatment of recurrent disease: 10 mg/kg once every 2 wk, or 15 mg/kg once every 3 wk. Continue treatment until progression of underlying disease.
Epithelial ovarian, fallopian tube & primary peritoneal cancer Front-line treatment: 15 mg/kg once every 3 wk in addition to carboplatin & paclitaxel for up to 6 cycles followed by continued use of bevacizumab as single agent for 15 mth or until disease progression, whichever come earlier. Treatment of recurrent disease: Platinum-sensitive: 15 mg/kg once every 3 wk in combination w/ carboplatin & paclitaxel for 6 cycles & up to 8 cycles; alternately, 15 mg/kg every 3 wk in combination w/ carboplatin & gemcitabine for 6 cycles & up to 10 cycles followed by continued use of Bevacizumab as single agent until disease progression. Platinum resistant: 10 mg/kg once every 2 wk in combination w/ 1 of the following agents: Paclitaxel, topotecan (given wkly) or pegylated lipos doxorubicin. Alternatively, administer 15 mg/kg every 3 wk in combination w/ topotecan on days 1-5, every 3 wk. Continue treatment until disease progression.
Cervical cancer In combination w/ one of the following: Paclitaxel & cisplatin or paclitaxel & topotecan: 15 mg/kg once every 3 wk. Continue treatment until progression of underlying disease.
Sign Out
